CN106187942B - 苯并噻唑酮化合物 - Google Patents
苯并噻唑酮化合物 Download PDFInfo
- Publication number
- CN106187942B CN106187942B CN201610536836.2A CN201610536836A CN106187942B CN 106187942 B CN106187942 B CN 106187942B CN 201610536836 A CN201610536836 A CN 201610536836A CN 106187942 B CN106187942 B CN 106187942B
- Authority
- CN
- China
- Prior art keywords
- compound
- present
- thiazol
- butoxyphenyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicinal Preparation (AREA)
- Emergency Medicine (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011079379 | 2011-09-06 | ||
| CNPCT/CN2011/079379 | 2011-09-06 | ||
| CN201280043386.3A CN103781771B (zh) | 2011-09-06 | 2012-09-05 | 苯并噻唑酮化合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280043386.3A Division CN103781771B (zh) | 2011-09-06 | 2012-09-05 | 苯并噻唑酮化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106187942A CN106187942A (zh) | 2016-12-07 |
| CN106187942B true CN106187942B (zh) | 2020-06-26 |
Family
ID=47010668
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610536836.2A Expired - Fee Related CN106187942B (zh) | 2011-09-06 | 2012-09-05 | 苯并噻唑酮化合物 |
| CN201280043386.3A Expired - Fee Related CN103781771B (zh) | 2011-09-06 | 2012-09-05 | 苯并噻唑酮化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280043386.3A Expired - Fee Related CN103781771B (zh) | 2011-09-06 | 2012-09-05 | 苯并噻唑酮化合物 |
Country Status (39)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3192B1 (ar) | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
| UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
| MA37872A1 (fr) * | 2012-08-30 | 2018-07-31 | Novartis Ag | Sels de composé benzothiazolone utilisés en tant qu'agoniste de beta-2-adrenoceptor |
| ES2646916T3 (es) | 2012-11-19 | 2017-12-18 | Bayer Pharma Aktiengesellschaft | Aminoimidazopiridazinas como inhibidores de MKNK1 cinasa |
| CA2897565A1 (en) * | 2013-02-28 | 2014-09-04 | Novartis Ag | Formulation comprising benzothiazolone compound |
| US10967119B1 (en) | 2019-04-01 | 2021-04-06 | Azizi Bilal | Wearable medication injecting device |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101065370A (zh) * | 2004-11-29 | 2007-10-31 | 诺瓦提斯公司 | 具有β－2－肾上腺素受体激动剂活性的5－羟基－苯并噻唑衍生物 |
| CN104736525A (zh) * | 2012-08-30 | 2015-06-24 | 诺华股份有限公司 | 作为β-2肾上腺受体激动剂的苯并噻唑酮化合物的盐 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3855801T2 (de) * | 1987-09-15 | 1997-07-03 | Rowett Research Inst | Anwendungsgebiete von beta-adrenergenen Agonisten |
| US20070082918A1 (en) * | 1993-11-02 | 2007-04-12 | Naftchi N E | Neurologically active compounds and compounds with multiple activities |
| GB9405019D0 (en) | 1994-03-15 | 1994-04-27 | Smithkline Beecham Plc | Novel compounds |
| ZA967892B (en) | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
| WO1999009018A1 (en) | 1997-08-14 | 1999-02-25 | Kirin Beer Kabushiki Kaisha | BENZOTHIAZOLONE DERIVATIVES HAVING SELECTIVE β2 RECEPTOR AGONIST ACTIVITY |
| CA2349616A1 (en) | 1998-12-04 | 2000-06-15 | Neurosearch A/S | New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| US6872723B2 (en) * | 2002-01-28 | 2005-03-29 | Wyeth | Stabilized difloxacin injectable solution |
| US6743797B2 (en) * | 2002-02-22 | 2004-06-01 | Chantest, Inc. | Methods for treating cardiac arrhythmia |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| PE20050130A1 (es) | 2002-08-09 | 2005-03-29 | Novartis Ag | Compuestos organicos |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| CA2520030A1 (en) * | 2003-03-26 | 2004-10-07 | Pharmacia & Upjohn Company Llc | Process to produce enantiomerically enriched alcohols and amines |
| BRPI0409198A (pt) * | 2003-04-04 | 2006-05-02 | Novartis Ag | derivados quinolin-2-ona para o tratamento de doenças de vias aéreas |
| BRPI0411275A (pt) | 2003-06-10 | 2006-08-01 | Kalypsys Inc | compostos de carbonila como inibidores de histona deacetilase para tratamento de doenças; composição farmacêutica; método de modular a atividade catalìtica de hdac; método de tratar doença em um indivìduo; utilização de um composto ou composição; método de inibir hdac |
| JP2007503472A (ja) * | 2003-06-10 | 2007-02-22 | カリプシス・インコーポレーテッド | 病気治療用のヒストン脱アセチル化酵素阻害剤としてのカルボニル化合物 |
| EP1646370A1 (en) | 2003-07-11 | 2006-04-19 | Glaxo Group Limited | Pharmaceutical formulations |
| EP1643974A1 (en) | 2003-07-11 | 2006-04-12 | Glaxo Group Limited | Inhalable pharmaceutical formulations comprising a sugar ester |
| ES2329586T3 (es) | 2003-11-21 | 2009-11-27 | Theravance, Inc. | Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino. |
| GB0328490D0 (en) | 2003-12-09 | 2004-01-14 | Glaxo Group Ltd | Medicinal compounds |
| JP2005187357A (ja) | 2003-12-25 | 2005-07-14 | Nippon Suisan Kaisha Ltd | 選択的なβ２受容体アゴニスト活性を有するベンゾチアゾロン誘導体の製造方法 |
| GB0402797D0 (en) | 2004-02-09 | 2004-03-10 | Novartis Ag | Organic compounds |
| CA2565243A1 (en) | 2004-05-13 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases |
| EP1595873A1 (de) | 2004-05-13 | 2005-11-16 | Boehringer Ingelheim Pharma GmbH & Co.KG | Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen |
| WO2006014704A1 (en) | 2004-07-21 | 2006-02-09 | Theravance, Inc. | DIARYL ETHER β2 ADRENERGIC RECEPTOR AGONISTS |
| DE102004045648A1 (de) | 2004-09-21 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika zur Behandlung von Atemwegserkrankungen |
| DE102005007654A1 (de) | 2005-02-19 | 2006-08-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen |
| TW200740781A (en) | 2005-08-29 | 2007-11-01 | Astrazeneca Ab | Novel compounds |
| TW200738659A (en) | 2005-08-29 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| WO2007086078A2 (en) | 2006-01-30 | 2007-08-02 | Panacea Biotec Ltd. | Novel pharmaceutical compositions and process of preparation thereof |
| CA2641880C (en) | 2006-02-10 | 2014-09-09 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| TW200745084A (en) | 2006-03-08 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| GB0613154D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| WO2008022038A1 (en) * | 2006-08-10 | 2008-02-21 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Preparation of (r,r)-fenoterol and (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure |
| TW200833670A (en) | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
| CA2685540C (en) | 2007-08-03 | 2018-10-16 | Graham Michael Wynne | Drug combinations for the treatment of duchenne muscular dystrophy |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| GB0814728D0 (en) | 2008-08-12 | 2008-09-17 | Argenta Discovery Ltd | New combination |
| GB0823140D0 (en) | 2008-12-18 | 2009-01-28 | Astrazeneca Ab | New combination |
| GB201009801D0 (en) | 2010-06-11 | 2010-07-21 | Astrazeneca Ab | Compounds 950 |
| GB201107985D0 (en) | 2011-05-13 | 2011-06-29 | Astrazeneca Ab | Process |
| JO3192B1 (ar) | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
| CA2897565A1 (en) | 2013-02-28 | 2014-09-04 | Novartis Ag | Formulation comprising benzothiazolone compound |
-
2012
- 2012-09-04 JO JOP/2012/0250A patent/JO3192B1/ar active
- 2012-09-05 MX MX2014002688A patent/MX345405B/es active IP Right Grant
- 2012-09-05 CU CUP2014000028A patent/CU24303B1/xx unknown
- 2012-09-05 EP EP12770249.6A patent/EP2753609B1/en active Active
- 2012-09-05 HU HUE12770249A patent/HUE030530T2/en unknown
- 2012-09-05 SG SG2014013114A patent/SG2014013114A/en unknown
- 2012-09-05 KR KR1020167007782A patent/KR101800140B1/ko not_active Expired - Fee Related
- 2012-09-05 KR KR1020147008777A patent/KR101628585B1/ko not_active Expired - Fee Related
- 2012-09-05 PH PH1/2014/500399A patent/PH12014500399A1/en unknown
- 2012-09-05 TW TW101132414A patent/TWI555738B/zh not_active IP Right Cessation
- 2012-09-05 ES ES12770249.6T patent/ES2615052T3/es active Active
- 2012-09-05 DK DK12770249.6T patent/DK2753609T3/en active
- 2012-09-05 UA UAA201401193A patent/UA114295C2/uk unknown
- 2012-09-05 MY MYPI2014000358A patent/MY163301A/en unknown
- 2012-09-05 LT LTEP12770249.6T patent/LT2753609T/lt unknown
- 2012-09-05 WO PCT/IB2012/054580 patent/WO2013035047A1/en not_active Ceased
- 2012-09-05 SI SI201230841A patent/SI2753609T1/sl unknown
- 2012-09-05 PE PE2014000312A patent/PE20141993A1/es not_active Application Discontinuation
- 2012-09-05 JP JP2014529113A patent/JP6130835B2/ja not_active Expired - Fee Related
- 2012-09-05 AU AU2013200422A patent/AU2013200422C1/en not_active Ceased
- 2012-09-05 EA EA201490573A patent/EA022909B1/ru not_active IP Right Cessation
- 2012-09-05 US US13/603,990 patent/US8933108B2/en not_active Expired - Fee Related
- 2012-09-05 HR HRP20170075TT patent/HRP20170075T1/hr unknown
- 2012-09-05 BR BR112014004732A patent/BR112014004732A2/pt not_active Application Discontinuation
- 2012-09-05 AP AP2014007462A patent/AP3830A/en active
- 2012-09-05 PT PT127702496T patent/PT2753609T/pt unknown
- 2012-09-05 UY UY0001034312A patent/UY34312A/es not_active Application Discontinuation
- 2012-09-05 CA CA2845766A patent/CA2845766A1/en not_active Abandoned
- 2012-09-05 CN CN201610536836.2A patent/CN106187942B/zh not_active Expired - Fee Related
- 2012-09-05 RS RS20161145A patent/RS55468B1/sr unknown
- 2012-09-05 PL PL12770249T patent/PL2753609T3/pl unknown
- 2012-09-05 CN CN201280043386.3A patent/CN103781771B/zh not_active Expired - Fee Related
- 2012-09-06 AR ARP120103276A patent/AR087787A1/es unknown
-
2014
- 2014-02-10 TN TNP2014000060A patent/TN2014000060A1/en unknown
- 2014-02-13 ZA ZA2014/01112A patent/ZA201401112B/en unknown
- 2014-02-27 IL IL231235A patent/IL231235A/en active IP Right Grant
- 2014-02-27 CL CL2014000493A patent/CL2014000493A1/es unknown
- 2014-03-04 GT GT201400042A patent/GT201400042A/es unknown
- 2014-03-06 CR CR20140114A patent/CR20140114A/es unknown
- 2014-03-06 CO CO14048375A patent/CO6900147A2/es not_active Application Discontinuation
- 2014-12-10 US US14/566,021 patent/US20150094346A1/en not_active Abandoned
-
2015
- 2015-02-03 ZA ZA2015/00790A patent/ZA201500790B/en unknown
- 2015-08-03 US US14/817,175 patent/US20150336914A1/en not_active Abandoned
- 2015-11-20 US US14/947,458 patent/US20160075670A1/en not_active Abandoned
-
2016
- 2016-06-10 US US15/178,579 patent/US9913828B2/en not_active Expired - Fee Related
-
2017
- 2017-02-02 CY CY20171100153T patent/CY1118585T1/el unknown
- 2017-03-01 JP JP2017038701A patent/JP6340103B2/ja not_active Expired - Fee Related
-
2018
- 2018-01-22 US US15/876,619 patent/US10251868B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101065370A (zh) * | 2004-11-29 | 2007-10-31 | 诺瓦提斯公司 | 具有β－2－肾上腺素受体激动剂活性的5－羟基－苯并噻唑衍生物 |
| CN104736525A (zh) * | 2012-08-30 | 2015-06-24 | 诺华股份有限公司 | 作为β-2肾上腺受体激动剂的苯并噻唑酮化合物的盐 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10251868B2 (en) | Benzothiazolone compound | |
| CN104736525B (zh) | 作为β-2肾上腺受体激动剂的苯并噻唑酮化合物的盐 | |
| HK1242680A1 (en) | Salts of benzothiazolone compound as beta-2-adrenoceptor agonist | |
| HK1196351A (en) | Benzothiazolone compound | |
| HK1196351B (en) | Benzothiazolone compound | |
| HK1206015B (en) | Salts of benzothiazolone compound as beta-2-adrenoceptor agonist | |
| NZ621089B2 (en) | Benzothiazolone compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200626 |